Company: AX
Filing Date: 2025-09-17
Form Type: 8-K
Source: 0001299709-25-000157
Chunk: 0

Company: Axos Financial, Inc.
Filing Date: 2025-09-17
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry Into A Material Definitive Agreement

On September 16, 2025, Axos Financial, Inc. (the “ Axos” or the “ Company”) entered into an underwriting agreement (the “ Underwriting Agreement”) with Keefe, Bruyette & Woods, Inc., as representative of the underwriters named therein, to issue and sell $200 million aggregate principal amount of the Company’s 7.00% Fixed-to-Floating Rate Subordinated Notes due 2035 (the “ Notes”), at a public offering price equal to 100% of the aggregate principal amount of the Notes (the “ Offering”).

The Company estimates that the net proceeds from the Offering will be approximately $197.2 million, after deducting underwriting discounts of 1.25% and expenses that are payable by the Company. The Offering is expected to close on or about September 19, 2025 (such date of closing, the '“ Closing Date”), subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds of the Offering to repay existing indebtedness, including the redemption in full of the 2030 Notes (as defined below), of which $160.5 million in principal amount is currently outstanding, and to support growth initiatives at the Company’s subsidiaries and for general corporate purposes.

The Underwriting Agreement contains customary representations, warranties and covenants between the parties as of the date of the Underwriting Agreement. These representations, warranties and covenants are not representations of factual information to investors about the Company or its subsidiaries, and the sale of any Notes pursuant to the Underwriting Agreement is not a representation that there has not been any change in the condition of the Company. A copy of the Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference. This description of the material terms of the Underwriting Agreement and the transactions contemplated thereby is qualified in its entirety by reference to such exhibit.

The Notes have been offered pursuant to a prospectus supplement, dated September 2025, to the prospectus dated February 2024 that forms part of the Company’s effective registration statement on Form S-3ASR (File No. 333-277514) filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended.

Item 8.01 Other Events